scholarly journals Impacts of LOC105371267 Variants on Breast Cancer Susceptibility in Northern Chinese Han Females: A Population-Based Case-Control Study

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Linna Peng ◽  
Congmei Huang ◽  
Shishi Xing ◽  
Dandan Li ◽  
Chunjuan He ◽  
...  

Background. LOC105371267, also known as PR-lncRNA1, was reported to be a p53-regulated long noncoding RNA (lncRNA), which played an essential role in the pathogenesis of breast cancer (BC). We aimed to observe the potential association between LOC105371267 polymorphisms and BC risk in Northern Chinese Han females. Methods. Totally, 555 healthy individuals and 561 patients with BC were recruited. Five candidate SNPs (rs6499221, rs3931698, rs8044565, rs3852740, and rs111577197) of LOC105371267 were genotyped with the Agena MassARRAY system. Odds ratio (OR) and 95% confidence intervals (CIs) were applied to evaluate the relationship of LOC105371267 genetic polymorphisms with BC susceptibility. Additionally, stratification analysis based on clinical features and haplotype analysis were also conducted. Finally, multifactor dimensionality reduction (MDR) analysis was performed to assess the SNP-SNP interaction among LOC105371267 variants, and false-positive report probability (FPRP) analysis was used to validate the result of this study. Results. In this study, rs3931698 was a protective factor of BC in total (GG homozygote: OR = 0.30, 95% CI: 0.11–0.82, p = 0.018 ; recessive model: OR = 0.30, 95% CI: 0.11–0.84, p = 0.021 ). In stratification analysis based on the average age of 52 years and clinical characteristics (PR status, III-IV TNM stage), rs3931698 was also demonstrated to be associated with BC susceptibility. In addition, rs6499221 and rs3852740 were also associated with BC susceptibility among patients at age <52 years and patients with BC in a positive status. Thus, the haplotype analysis had a negative result for the incidence of BC ( p > 0.05 ), and haplotype consisting of rs8044565 and rs111577197 was nonsignificantly associated with the BC risk. Finally, MDR and FPRP analyses also validated the result of this study. Conclusion. Polymorphisms rs3931698, rs6499221, and rs3852740 of LOC105371267 were found to be associated with the risk of BC in total, and stratification analysis in the Northern Chinese Han females suggested that LOC105371267 variants might be helpful to predict BC progression.

2020 ◽  
Author(s):  
Xiaoli Liu ◽  
Dandan Li ◽  
Chunjuan He ◽  
Linna Peng ◽  
Shishi Xing ◽  
...  

Abstract Background: LOC105371267 (also known as PR-lncRNA1) was reported to be a p53-regulated lncRNA, which played essential roles in the pathogenesis of breast cancer (BC). We aimed to investigate the potential associations between LOC105371267 polymorphisms and BC risk. Method: Totally, 555 healthy individuals and 561 BC patients were recruited. Five candidate SNPs of LOC105371267 were genotyped with Agena MassARRAY system. Odds ratio (OR) and 95% confidence intervals (CIs) were applied to evaluate the relationship of LOC105371267 with BC susceptibility. Additionally, stratification analyses based on clinical features and haplotype analysis were also conducted. Results: A decreased BC risk was observed rs3931698 GG genotype (OR = 0.30, P = 0.018) and recessive genetic model (OR = 0.30, P = 0.021). Stratified analysis with age also revealed that this SNP was associated with a lower risk at age < 52 years. Meanwhile, multiple clinical characteristics, including ER and PR status and stage were all correlated with SNPs rs6499221, rs3931698, rs3852740 and rs8044565.Conclusion: Four LOC105371267 SNPs (rs6499221, rs3931698, rs8044565 and rs3852740) were found to be correlated with development of BC. Additionally, ER, PR, and stage were also linked to LOC105371267 polymorphisms, providing novel diagnostic and therapeutic targets for of BC management.


2020 ◽  
Vol 86 ◽  
pp. 106756
Author(s):  
Zhenghua Wang ◽  
Xiaoyu Wang ◽  
Yu Gao ◽  
Yuanyuan Wang ◽  
Minghao Xu ◽  
...  

2011 ◽  
Vol 30 (2) ◽  
pp. 111-116 ◽  
Author(s):  
Jinghua Ren ◽  
Xiaoling Wu ◽  
Wenshan He ◽  
Jun Shao ◽  
Bo Cheng ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (8) ◽  
pp. e0135865 ◽  
Author(s):  
Yu-Mian Jia ◽  
Yun-Tao Xie ◽  
Ya-Jun Wang ◽  
Ji-Yuan Han ◽  
Xin-Xia Tian ◽  
...  

2020 ◽  
Author(s):  
Tianbo Jin ◽  
Linna Peng ◽  
Shishi Xing ◽  
Dandan Li ◽  
Chunjuan He ◽  
...  

Abstract Purpose LRRC3B gene, as a tumor suppressor gene was involved in the development and progress of breast cancer (BC). However, the effect of LRRC3B polymorphisms on BC has rarely been reported. In the study, we aims to evaluate the relation between LRRC3B variants and BC risk. Methods Among 563 BC patients and 552 healthy controls, ten single-nucleotide polymorphisms (SNPs) in LRRC3B were genotyped by Agena MassARRAY. Odds ratios (OR) and 95% confidence interval (CI) was calculate using logistic regression model. Results Our study demonstrated that rs1907168 polymorphism (OR = 0.71, p = 0.017) reduced the risk of BC in the overall. In stratified analyses by age, rs1907168 decreased (OR = 0.53, p = 0.002) while rs78205284 (OR = 2.83, p = 0.034) increased BC susceptibility among the population at age ≤ 51 years. Clinical parameters such as tumor size, the status of PR and Ki67 were associated with LRRC3B variants. Furthermore, we found that the association of ‘GATT’ haplotype with an increased risk for BC. In addition, LRRC3B gene was down-regulated in BC tumor and had a poor prognosis in BC in silico analysis. Conclusion Our study firstly found LRRC3B SNPs contributed to the risk of BC, suggesting LRRC3B variants might help to predict BC progression.


Meta Gene ◽  
2017 ◽  
Vol 14 ◽  
pp. 1-5 ◽  
Author(s):  
Shekoufeh Hassanzarei ◽  
Mohammad Hashemi ◽  
Hedieh Sattarifard ◽  
Seyed Mehdi Hashemi ◽  
Gholamreza Bahari

Sign in / Sign up

Export Citation Format

Share Document